ESO-ESMO LATIN-AMERICAN MASTERCLASS IN Lima.pdfHeld in collaboration with Under the auspices of...

Held in collaboration with Under the auspices of

LATIN-AMERICA PROGRAMME

5TH ESO-ESMO LATIN-AMERICAN MASTERCLASS IN

CLINICAL ONCOLOGY

3-7 April 2019Lima, Peru Chairs:A. Cervantes, ES - N. Pavlidis, GRR.A. Stahel, CH

Scientific Co-ordinators:M. Aapro, CH - F. Cardoso, PT

MCO Lima (6 Nov)_screen 06.11.2018 11:27 Pagina 3

FOREWORDThe Masterclass is the most structured ESO educational activity whose format has been established and presented in Europe for over a decade. The success of the teaching method hasbeen confirmed by the events held also in other parts of the world as well as by the three editions held in Latin America. It is with pleasure and gratefulness for the consideration of thelocal community, that ESO announces the fifth edition to be held in the region in 2019. The Masterclass offers plenary lectures discussing current issues and controversies as well as critically reviewing significant therapeutic developments. State-of-the-art data recognized byESMO and other evidence-based guidelines will be cited. Participants will deliver case presentations within tumour boards and small groups and discuss them with the chairs and thefaculty. As for all Masterclasses, the number of participants will be limited and admission will beby competitive application only. Admitted participants will be granted free registration and half-board accommodation for the duration of the Masterclass.

TEACHING FORMATThe Masterclass offers plenary lectures regarding state-of-the-art clinical evaluation and treatments with reference to clinical guidelines and which will conclude in take-home messages.The clinical sessions will be complemented by tumour board discussions supported by regionaltutors. Furthermore, participants will deliver case presentations within small groups and discussthese with the chairs and the faculty. In preparation of the attendance, participants will be requested to follow four selected e-ESO sessions (www.e-eso.net). All participants will reside at the course venue and participation is compulsory throughout thecourse. The Masterclass will be entirely in English and at least an intermediate level of English isnecessary for admission.

LEARNING OBJECTIVES• Improve medical oncologists’ skills• Practising case discussions• Deep focus on breast, gastro-intestinal, genitourinary, gynaecological, head and neck and lung cancers• Compact update on further topics of interest

THE MASTERCLASS IS:• A 5-day residential educational event• Full immersion• Clinically-oriented• Multidisciplinary• Delivered by an international faculty of experts

IDEAL PROFILE OF THE MASTERCLASS CANDIDATE• Age between 30 and 40 years• At least 2-3 years’ experience in medical oncology • Involvement in scientific activities (desirable)• At least an intermediate level of English language (simple scientific discussion in English)• Practicing in Latin-America

LANGUAGEThe Masterclass will be held in English and translation will not be provided.

INSURANCEThe organisers bear no responsibility for untoward events in relation to the participation in the event. Participants will be advised to take out their own personal and travel insurance coverage.

CME AND ESMO MORA ACCREDITATION AND CERTIFICATESApplication for CME recognition will be submitted to the Accreditation Council of Oncology in Europe (ACOE) and to the European Accreditation Council for Continuing Medical Education(EACCME). EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA). Information on the status of the applications can be obtainedfrom the organising secretariat. Participants will be entitled to receive a certificate of attendance atthe close of the event by completing the on-line evaluation questionnaire. Furthermore, application for the ESMO-MORA points is in process.

Chairs:

Scientific Co-ordinators:


FACULTY (as of November 2018)

M.S. Aapro, Clinique de Genolier, Genolier, CH

J.Y. Blay, Centre Léon Bérard, Lyon, FR

M.T. Bourlon, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, MX

F. Calvo, Clinica Universidad de Navarra, Madrid, ES

F. Cardoso, Champalimaud Cancer Center, Lisbon, PT

L. Casanova Marquez, Clínica ALIADA, Lima, PE

F. Cavalli, Oncology Institute of Southern Switzerland, Bellinzona, CH

A. Cervantes, University Clinical Hospital, Valencia, ES

G. Curigliano, European Institute of Oncology, Milan, IT

E. Efstathiou, University of Texas MD Anderson Cancer Center, Houston, US

S.X. Franco, Clinical del Country, Bogota, CO

F. Geara, The American University of Beirut Medical Center, Beirut, LB

H. Gomez Moreno, Sociedad Peruana de Cancerologia, Lima, PE

J. Jeronimo, Global Coalition Against Cervical Cancer (GC3), Damascus, US

D. Lorusso, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT

L. Mas Lopez, Instituto Nacional de Enfermedades Neoplásicas, Lima, PE

O. Michielin, Lausanne University Hospital – CHUV, Lausanne, CH

S. Neciosup, Instituto Nacional de Enfermedades Neoplasicas, Lima, PE

N. Pavlidis, University Hospital, Ioannina, GR

E. Payet, Instituto Nacional de Enfermedades Neoplásicas, Lima, PE

F.A. Peccatori, European School of Oncology and European Institute of Oncology, Milan, IT

F. Penault-Llorca, Centre Jean Perrin, Clermont-Ferrand, FR

C. Santos, Instituto Nacional de Enfermedades Neoplásicas, Lima, PE

R.A. Stahel, University Hospital, Zurich, CH

R.M. Terra, University of São Paulo Medical School, São Paulo, BR

C. Vallejos, Oncosalud, Lima, PE

E. Van Cutsem, University Hospital Gasthuisberg, Leuven, BE

J.B. Vermorken, University Hospital Antwerp, Edegem, BE


PRELIMINARY PROGRAMME

Wednesday, 3 April

13:00 Lunch

14:15 Welcome and introduction

14:25 Spotlight session

• The magnitude of the cancer problem in my country H. Gomez Moreno, PE • Discussion

14:55 Clinical session Genito-urinary cancers (I) E. Efstathiou, US Prostate cancer:

• Active surveillance or watchful waiting M.T. Bourlon, MX

• Local therapy: Surgery and radiotherapy F. Geara, LB

• First-line endocrine treatment E. Efstathiou, US

• Endocrine-resistant-refractory E. Efstathiou, US

• Discussion

17:15 Coffee break 17:30 Clinical session Genito-urinary cancers (II) Chair: to be confirmed

• Treatment of bladder cancer C. Vallejos, PE

• Metastatic renal cancer: Evidence-based treatment Speaker to be confirmed

• Discussion 19:10 Tumour board Genito-urinary cancers C. Vallejos, PE • Participants' case presentations 20:30 Welcome dinner

Thursday, 4 April

8:30 Clinical session Breast cancer (I) Chair: G. Curigliano, IT

• What the clinician needs to know about breast pathology and sample quality F. Penault-Llorca, FR

• Genomic tests in clinical practice F. Penault-Llorca, FR

• (Neo-) adjuvant chemotherapy and biological agents G. Curigliano, IT

• (Neo-) adjuvant endocrine therapy F. Cardoso, PT

• Discussion 10:30 Coffee break

10:50 Clinical session Breast cancer (II) Chair: F. Cardoso, PT

• Recommended management of HER-2+ advanced breast cancer F. Cardoso, PT


• Recommended management for triple-negative advanced breast cancer G. Curigliano, IT

• Recommended management for ER+ advanced breast cancer S.X. Franco, CO

• ABC Global Alliance F. Cardoso, PT • Discussion 12:45 Tumour board Breast cancer S.X. Franco, CO • Participant's case presentations 13:45 Lunch

14:40 Spotlight session O. Michielin , CH

• Melanoma (Videoconference) • Discussion

15:15 Spotlight session • Opportunities and limitations of liquid biopsies F. Penault-Llorca, FR • Discussion 15:50 Spotlight session • Treatment of elderly patients M. Aapro, CH • Discussion 16:25 Coffee break

16:45 Spotlight session • Management of cancer in young women F. Cardoso, PT • Discussion 17:20 Spotlight session • Fertility preservation and pregnancy in cancer patients F.A. Peccatori, IT • Discussion 17:55 Spotlight session • Management and treatment of toxicity M. Aapro, CH • Discussion

Friday, 5 April 8:30 Clinical session Gynaecological cancers Chair: J.B. Vermorken, BE

• New classification of gynaecologic cancers F. Penault-Llorca, FR • Ovarian cancer: Surgical and systemic treatment D. Lorusso, IT • Cervical cancer: Primary and secondary prevention J. Jeronimo, US • Cervical cancer: Systemic treatment D. Lorusso, IT • Management of endometrial cancer J.B. Vermorken, BE • Radiotherapy of gynaecological malignancies F. Geara, LB • Discussion

11:20 Coffee break


11:40 Tumour board Gynaecological cancers C. Santos, PE • Participant's case presentations 12:10 Spotlight session • Cancer of unknown primary N. Pavlidis, GR

• Discussion 12:50 Lunch 14:00 Clinical session Head and neck cancer Chair: J.B. Vermorken, BE

• When to operate? Speaker to be confirmed

• When to irradiate? F. Calvo, ES

• Systemic therapy and radio-chemotherapy J.B. Vermorken, BE

• Discussion 16:05 Tumour board Head and neck cancer Tutor to be confirmed • Participant's case presentations 16:40 Coffee break

17:00 Group sessions (four/five groups) Tutors: L. Casanova Marquez, PE L. Mas Lopez, PE - S. Neciosup, PE • Part I: Clinical case presentations by participants • Part II: Selected participants present their national

situation ("How is cancer treated in my country")

Saturday, 6 April 8:30 Clinical session Gastro-intestinal tumours (I) Chair: A. Cervantes, ES

• Adjuvant and neo-adjuvant treatment of colorectal cancer E. Van Cutsem, BE

• Systemic treatment in advanced disease (including liver) E. Van Cutsem, BE


10:10 Clinical session Gastro-intestinal tumours (II) Chair: E. Van Cutsem, BE

• Management of early rectal cancer: Any role for adjuvant chemotherapy? A. Cervantes, ES

• Systemic treatment in early and advanced gastric cancers and esophageal cancer A. Cervantes, ES

• Pancreatic and biliary tract cancers E. Van Cutsem, BE

• Discussion 12:10 Tumour board Gastro-intestinal tumours E. Payet, PE • Participant's case presentations 13:10 Lunch


14:10 Spotlight session

• Sarcoma and GIST (Videoconference) J.Y. Blay, FR • Discussion 15:05 Spotlight session

• Has immunotherapy kept its promises in malignant lymphomas (videoconference) F. Cavalli, CH

• Discussion 15:45 Spotlight session

• ESMO guidance on evaluation of treatment benefit R. Stahel, CH


16:45 Group sessions Tutors: L. Casanova Marquez, PE L. Mas Lopez, PE - S. Neciosup, PE • Part I: Clinical case presentations by participants • Part I: Selected participants present their national

situation ("How is cancer treated in my country") 19:00-19:30 Sponsored Lecture

20:30 Farewell dinner

Sunday, 7 April 8:30 Clinical session Lung cancer (I) Chair: R.A. Stahel, CH • Molecular classification of lung cancer for

clinical practice F. Penault-Llorca, FR • Surgery R.M. Terra, BR

• Radiotherapy F. Calvo, ES

• Non-small cell lung cancer systemic therapy R.A. Stahel, CH


11:20 Clinical session Lung cancer (II) Chair: R.A. Stahel, CH • Small cell lung cancer R.A. Stahel, CH

• Discussion 11:55 Tumour board Lung cancer Faculty and tutor: • Participant's case presentations R. Terra, BR 12:55 Learning assessment test 13:40- Lunch followed by departures 14:40


GENERAL INFORMATION

HOW TO APPLYInterested oncologists should apply online at www.eso.net providing the following documents:• Letter describing motivation for attending;• Support letter from head of department or mentor;• CV with list of publications (if the list is not provided, it will be assumed that no papers have

been published);• Clinical case abstract (see below).

Clinical case abstractApplicants are requested to submit an abstract describing a clinical case related to one of thesubjects of the Masterclass (breast, gastro-intestinal, genito-urinary, gynaecological, head andneck, and lung cancers).It is suggested that, among the subjects of the Masterclass, the clinical case is on a tumour typethat the applicant does not see frequently but that could add to the overall educational contentsof the Masterclass. On the contrary, it is recommended that the case reflects the participant’sdaily practice, avoiding uncommon or extremely rare cases which may have a lower educationalimpact.The clinical case abstract should include diagnostic considerations, treatment, results and follow-up, at least three questions proposed for discussion.Admitted participants will have the opportunity to present the clinical case in the format of a clinical grand round discussion to the chairs, tutors, other faculty members and participants. The one-page abstract should be submitted on-line using the template available atwww.eso.net, or by entering it in the application form.

The application outcome will be notified by e-mail by begin of February.

ORGANISING SECRETARIAT European School of OncologyPiazza Indipendeza 2 | 6500 Bellinzona | SwitzerlandLuis CarvalhoPh: +41 91 820 09 58 | E-mail: [email protected]

ATTENDANCE TO THE MASTERCLASS IS BY APPLICATION ONLYSuccessful applicants are granted free registration and half-board accommodation

APPLICATION DEADLINE: 7 JANUARY 2019Information and online application are available at www.eso.net


ESO-ESMO LATIN-AMERICAN MASTERCLASS IN Lima.pdfHeld in collaboration with Under the auspices of...

Documents

Transcript of ESO-ESMO LATIN-AMERICAN MASTERCLASS IN Lima.pdfHeld in collaboration with Under the auspices of...